A broad-scale ground survey of macropod abundance in north-eastern New South Wales was undertaken in 1989-90. The survey area was stratified into an eastern and western region, and within regions by habitat on the basis of vegetation and topographic criteria. Macropod density in each stratum was estimated from walked line transect counts for five species: Macropus giganteus, Macropus robustus, Macropus parryi, Macropus rufogriseus and Wallabia bicolor. Within sampled strata, macropod density was substantially higher in the western region than in the eastern region. Macropus parryi occurred in only trace numbers in the eastern region, with the number of sightings too small for reliable density estimation. No M. parryi were sighted in the western region. Macropus giganteus and M. rufogriseus were the dominant species in sampled strata in the eastern region, while M. giganteus and M. robustus were dominant in the west. Overall, pre-survey activities of habitat digitising and liaison with landholders required approximately the same effort as actual survey work. Liaison with landholders required relatively more time in the eastern region, where human population was higher, than in the western region. Incomplete coverage of planned transect routes, due mainly to impenetrable vegetation, lead to a positive bias of no more than 10-20% in population estimation for M. giganteus and M. robustus, and an unknown bias for the other species. The use of broad vegetation information on 1 : 100 000 map sheets for habitat stratification limited the scale at which analysis of sightability could be undertaken. Macropus giganteus and M. robustus are commercially harvested in the western region. Annual commercial harvest rates in the three years prior to the survey were conservatively estimated to be less than 0.9% for M. robustus and less than 5.4% for M. giganteus.

No abstract

The image qualities of 105 mm film (Cronex MRF-21) and a conventional screen-film (Hi-Plus/Cronex 4) were compared for gastrointestinal studies, a high-contrast-resolution procedure, using a General Electric MPX 100/Fluoricon 300 x-ray system. The high These results were achieved with a reduction in radiation dose of 55%.

Continued smoking after diagnosis jeopardizes cancer survivors' health and well-being. Quitline-based smoking cessation treatment is convenient, widely available and free, yet the appropriateness of this treatment approach for survivors is not known. We assessed satisfaction among participants in an enhanced quitline intervention as part of a randomized clinical trial assessing feasibility. Methods: We recruited cancer survivors through the NCI Community Clinical Oncology Program (CCOP) network within 6 months of treatment who smoked within the last 7 days and randomized them 2:1 to an enhanced quitline-based intervention (brief in-person motivational interviewing counseling session, quitline telephone counseling, 6 weeks of nicotine replacement patches) or usual care. We collected treatment satisfaction data and self-reported smoking status at 12 weeks and confirmed smoking status for reported non-smokers using a semi-quantitative urinary cotinine assessment. Results: We enrolled 146 survivors (75% female, 79% non-Hispanic white, mean age ¼ 58 years). At entry, survivors reported smoking an average of 15 cigarettes per day; 77% reported smoking within 30 minutes of awakening. Assessments were completed by 63% of the quitline group and 75% of the usual care group at 12 weeks (P > 0.05). 83% of participants in the intervention arm (n ¼ 98) completed at least one quitline call, and 18% completed !3 calls. Use of nicotine patches was 61% in the quitline group and 42% in usual care. Quitline participants were generally satisfied with both the inperson counseling (mean satisfaction score ¼ 4.2 (SD ¼ 1.0), on 1-5 scale) and the quitline telephone counseling (mean satisfaction score ¼ 3.4 (SD ¼ 1.3)). 87% would recommend the quitline program to others. Self-reported 7-day point prevalence cessation was 26% in the quitline group and 17% in the usual care arm (P ¼ 0.33). Conclusions: An enhanced quitline smoking cessation intervention appears to be acceptable to cancer survivors and to result in a trend towards slightly higher cessation at 12 weeks. Increased efforts to retain survivors in treatment and encourage the use of nicotine replacement may be necessary to increase the impact of this intervention approach. Breast cancer survivors may experience deterioration of physical function. This is important because poor physical function may be associated with premature mortality, injurious falls, bone fracture, and disability. We conducted a post hoc analysis to explore the potential efficacy of slowly-progressive weight lifting to reduce the incidence of physical function deterioration among breast cancer survivors. Methods: Between October 2005 and August 2008, we conducted a single-blind, 12-month, randomized controlled trial of twice-weekly slowlyprogressive weight lifting or standard care among 295 nonmetastatic breast cancer survivors. In this post hoc analysis of data from the Physical Activity and Lymphedema Trial, we examined incident deterioration of physical function after 12-months, defined as a !10-point decl...

No abstract